Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine CandidateBusiness Wire • 12/22/22
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine CandidateBusiness Wire • 08/24/22
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive OfficerBusiness Wire • 06/23/22
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific ReportsBusiness Wire • 06/14/22
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of CoronavirusesBusiness Wire • 04/06/22
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1Business Wire • 03/22/22
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1Business Wire • 03/10/22
Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint ManuscriptBusiness Wire • 03/03/22
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of QuorumBusiness Wire • 01/26/22
OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph TodayInvestorPlace • 01/04/22